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Background: A chronic inflammation resulting from an imbalance between pro-inflammatory and anti-inflammatory
cytokines in Hashimoto’s thyroiditis (HT) might be responsible for IR in hypothyroidism. This study was performed to
investigate a probable association between autoimmune background of hypothyroidism and IR.
Methods: In this clinical study, 63 subjects with Hashimoto’s thyroiditis and 49 subjects with post-ablation hypothyroidism
were enrolled. All the participants were euthyroid for more than one year through Levothyroxine therapy. Serum
concentrations of Thyroid-stimulating Hormone (TSH), Free Thyroxin (FT4, FT3), Anti-Thyroid Peroxidase Antibodies
(Anti-TPO Abs), Total Cholesterol (TC), HDL-Cholesterol (HDL-C), Triglyceride (TG), Fasting Blood Glucose (FBG), and
insulin levels were measured and Oral Glucose Tolerance Test (OGTT) was performed for all of the subjects. Participants
with anti TPO levels more than 1000 IU /ml were classified as having highly positive antibodies.
Results: No significant differences regarding to plasma insulin, glucose and lipid concentration, were detected
between subjects with and without Hashimoto’s thyroiditis. However, subjects with highly positive Anti TPO Abs had
higher prevalence of elevated fasting insulin level than those with lower titers of Anti TPO Abs and subjects without
autoimmune background (94.1% vs. 62.8% and 71.4% respectively, P = 0.05). Subjects with highly positive titers of Abs
also had a lower serum HDL-c levels than the rest of the subjects (40.6 ± 2.1 vs. 47.2 ± 1.7 and 47.4 ± 1.4, P = 0.04).
Conclusions: There is no obvious association between thyroid autoimmunity and metabolic indexes of hypothyroid
patients. Only patients with Ani TPO antibody levels more than 1000 IU/ml may experience higher insulin level and less
HDL-c with the same BMI.
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Hypothyroidism has been reported in 1% to 10% of the
adult population [1] and is accompanied by a number of
important health implications including increased risk of
dyslipidemia, altered peripheral glucose disposal due
to insulin resistance and cardiovascular disorders [2,3].
Insulin resistance is a key factor in the pathogenesis of
type 2 diabetes mellitus (DM), metabolic syndrome and
atherosclerosis [1,4]. It is established that hypothyroidism
constitutes to insulin resistant state [5,6]. Furthermore,
some studies have shown that even a subtle increase in
plasma TSH levels within the physiological range may* Correspondence: mazaheri_tina@yahoo.com
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unless otherwise stated.affect insulin secretion [7] and may be associated with
insulin resistance and metabolic syndrome [8]. However,
the exact mechanism connecting hypothyroidism to IR is
still unclear. The fact that overt hypothyroidism and even
subclinical hypothyroidism have been associated with
disorders of glucose and insulin metabolism [9,10] and
that thyroid replacement therapy has been unable to
restore Insulin Mediated Glucose Uptake (IMGU) to its
physiological state suggests that molecular and cellular
interactions other than the thyroid hormones are involved
in the insulin resistance state [11].
Since Hashimoto’s thyroiditis is the most common cause
of hypothyroidism in areas with sufficient iodine intake
[12], a chronic inflammation resulting from an imbalance
between pro-inflammatory and anti-inflammatory cytokinesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Mazaheri et al. Journal of Diabetes & Metabolic Disorders 2014, 13:103 Page 2 of 7
http://www.jdmdonline.com/content/13/103[13] in this disease might be the mechanism responsible
for IR in hypothyroidism. Considering these theory
non-autoimmune and non-inflammatory causes of hypo-
thyroidism would not contribute to IR.
To illustrate a probable association between autoimmune
background of hypothyroidism and IR this study was
conducted. In this study we compared insulin resistance
and dysglycemia in hypothyroid patients with and without
autoimmunity after attainment of a euthyroid state through
levothyroxine therapy.Materials and methods
Subjects
A total of 112 adult hypothyroid patients including 63
subjects with Hashimoto’s thyroiditis and 49 people with
post ablation hypothyroidism who were randomly selected
from Valiasr Hospital outpatient endocrine clinic, an
academic general hospital in Zanjan, enrolled in this
study. Diagnosis of hypothyroidism was conducted if
serum TSH concentration was more than 5 IU/ml, and
serum T4 concentration was less than 64 · 5 nmol/l.
Individuals with serum TSH level more than 10 IU/ml
accompanied by normal T4 and T3 levels, were consid-
ered as subclinical hypothyroid. All hypothyroid patients
with enlarged rubbery thyroid and high serum Anti-
TPO Abs concentration were categorized as Hashimoto’s
thyroiditis while those with history of thyroid surgery or
radioiodine ablation performed in more than a year period
of time and without any anti-thyroid antibodies in their
blood were recognized as post ablation hypothyroid.
Having a list of all hypothyroid patients of the clinic,
they were categorized under Hashimoto’s thyroiditis and
post-ablation hypothyroidism based on their documented
medical history. Inclusion criteria were hypothyroid par-
ticipants who underwent Levothyroxine therapy in an
appropriate dosage by which the patient was euthyroid at
least for one year. Patients with diabetes mellitus, cardio-
vascular disease, cerebral vascular disease, corticosteroid
consumption, pregnancy, chronic liver disease, thyroid
cancer, renal dysfunction and any autoimmune disease
like lupus erythematous and Rheumatoid arthritis were
excluded from the study. None of the selected individuals
were under medication known to affect glucose or lipid
metabolism.
At the beginning of the study anti-thyroid antibodies
including anti thyroglobulin and Anti TPO levels were
measured again for all the eligible participants and those
with positive anti thyroid antibodies in the post ablation
hypothyroid group were excluded from the study.
After exclusion of two subjects due to DM in Hashimoto’s
thyroiditis group and 16 subjects from post-ablation
hypothyroid group including 6 people with mild ele-
vated Anti TPO Abs, four people with history of thyroidcancer, five subjects who did not complete the study
and one person with DM, 112 patients were studied.
All the participants were informed orally about the
aim of study and informed consents were obtained from
them. This study was approved by the ethical committee
of Zanjan Univesity of Medical Sciences in Iran.
Measurements
Clinical examination and Anthropometric Measurements
carried out for all the patients by the researcher. Height
was measured with a stadiometer to the nearest 0.5 cm.
Body weight was recorded by calibrated digital scale
while wearing light clothes. Blood pressure values were
measured twice on the left upper arm; in the sitting
position with a random zero sphygmomanometer after
a 10-min rest. Waist circumference between the iliac
crest and the lowest rib at umbilicus level was measured
using flexible tape. Body Mass Index (BMI) was also
calculated accordingly. Demographic information and
family history of diabetes and hypertension were obtained
from the participants. Duration of replacement therapy
with Levothyroxine-sodium, plasma TSH levels in the
first diagnosis of hypothyroidism state and TSH plasma
levels at the time of study were explored and documented
specifically. In order to select only euthyroid patients,
those with TSH or FT3 values below or above the normal
range were excluded from further analysis.
Blood samples were collected from the ante-cubital
vein of the participants after at least 12 hours of fasting.
Serum concentrations of TSH, FT4, FT3, Anti TPO Abs,
Total Cholesterol (TC), HDL-cholesterol (HDL-C), Trigly-
ceride (TG), glucose and insulin were measured. After-
wards, an Oral Glucose Tolerance Test (OGTT) with 75
gr of glucose was performed for all the participants.
Obesity was defined as BMI ≥30 kg/m2, central obesity
as a waist circumference ≥102 cm in men and ≥88 cm in
women, low HDL as serum HDL cholesterol ≤40 mg/dl
in men and ≤50 mg/dl in women. Serum triglycer-
ides ≥150 mg/dl, total cholesterol level ≥240 mg/dl,
fasting insulin >6 uIU/mL and fasting plasma glu-
cose ≥100 mg/ dl were considered as hypertriglyceridemia,
hypercholesterolemia, elevated fasting insulin level and
hyperglycemia respectively. Hypertension defined as sys-
tolic blood pressure more than 130/85 mmHg. TPO Ab
level of more than 80 U/ml was positive. People with anti
TPO levels more than 1000 IU /ml were categorized as
having highly positive antibodies and analyzed separately.
Laboratory measurements
Biochemical variables measurements were done at the
laboratory of Vali-e-asr Hospital, using commercial kits:
Plasma glucose was measured by the glucose peroxidase
colorimetric enzymatic method, with a sensivity of 5 mg/dl.
Serum cholesterol and triglyceride (TG) were measured by
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density lipoprotein (LDL-C) estimation was calculated
using the Friedewald formula. Insulin resistance was
estimably assessed by the homeostasis model assessment
index (HOMA-IR = (fasting glucose (mmol/l) × fasting
insulin (uIU/mL)/22.5).TSH concentrations were mea-
sured by Immuno Chemiluminescense assay. Anti-TPO
was determined by radioimmunoassay (RIA) system
(SorinBiomedia, Italy).
Statistics
Statistical analyses were done using SPSS 16.5 software
package. Data are expressed as mean ± SE or medium
where is appropriate. Differences between two groups were
tested using Student’s unpaired t-test (or Mann–Whitney
according to sample distribution). For an analytic compari-
son of the variables between three groups with and without
a normal distribution, Fisher test and Kruskal-Wallis test,
were utilized respectively. ϰ 2 test was performed to assess
the significance of differences between proportions. To
determine the correlation between the serum anti TPO
antibody concentration and other variables Regression
analysis was employed. P < 0.05 was considered to specify
statistical significance.
Results
A total of 112 hypothyroid patients including 98 (88%)
women and 14 (12%) men with the mean age of 41.8 ±
12.8 years were studied. Basal clinical and laboratory char-
acteristics of the two groups of patients with Hashimoto’s
thyroiditis and post-ablation hypothyroidism are compared
in Table 1. Based on the data, no significant differenceTable 1 Comparison of the biochemical and anthropometric
parameters in two groups of patients based on their






Age (year) 43.9 ± 1.7 39.9 ± 1.5 0.103
W.C (cm) 89.5 ± 3.1 92.6 ± 1.4 0.696
BMI (kg/m2) 28.5 ± 0.6 28.1 ± 0.6 0.741
SBP 113.3 ± 3.1 114.6 ± 2.2 0.677
DBP 72.2 ± 2 76.1 ± 1.8 0.126
TC (mmol/L) 189.2 ± 6 179.1 ± 5.6 0.266
TG (mmol/L) 134.4 ± 7.3 147.9 ± 11.6 0.935
HDL (mmol/L) 47.4 ± 1.4 45.6 ± 1.4 0.232
FPG (mmol/L) 93 ± 1.6 90.5 ± 1.7 0.452
OGTT 112.9 ± 3.7 108.2 ± 4.5 0.181
Insulin (uIU/mL) 8.9 ± 0.6 10.7 ± 1.1 0.615
HOMA-IR 2.1 ± 0.2 2.4 ± 0.3 0.913
WC: Waist Circumference; BMI: Body Mass Index; SBP: Systolic Blood Pressure; DSB:
Diastolic Blood Pressure; TC: Total cholesterol; TG: Triglyceride; HDL: High Density
Lipoprotein; FPG: Fasting Plasma Glucose, OGTT: Oral Glucose Tolerance Test.regarding to clinical and biochemical variables was found
between the hypothyroid patients with and without auto-
immune background. Although serum levels of TG
and HOMA-IR were relatively higher in patients with
Hashimoto’s thyroiditis, the difference was not statistically
significant.
Regarding to HOMA-IR, 50 subjects (44.6%) of hypo-
thyroid patients were insulin resistant including 26 (41.2%)
patients with Hashimoto’s thyroiditis and 24 (48.9%)
patients with post ablation hypothyroidism (P: 0.232).
Patients with Anti TPO antibody levels more than
1000 IU/ml were classified as having highly positive anti-
bodies, and were separately analyzed. Table 2 shows the
difference between the three groups of patients for fre-
quency of obesity, central obesity, hypercholesterolemia,
hypertriglyceridemia, low-HDL cholesterol and hypergly-
cemia. The prevalence of hyperinsulinemia was signifi-
cantly higher in Hashimoto patients with higher levels of
Anti TPO antibodies more than 1000 IU/ml (Table 2).
Table 3 illustrates an overview of the biochemical and
anthropometric parameters in the group with highly
positive anti thyroid antibodies and compares it with
other hypothyroid patients. The data reveals that beside
HDL-c which was significantly lower in patients with
high levels of anti thyroid antibody, other parameters
like insulin resistance were not different between the
three groups.
Table 4 refers to the relationship between the serum
level of Anti TPO antibody and other variables.
The mean duration of hypothyroidism in our patients
was 5.5 ± 7.9 years. Participants were categorized into
two groups based on Levothyroxine therapy duration.
Glucose concentration and insulin resistance index of
subjects who had been diagnosed with hypothyroidism
and had received treatment within the past 5 years does
not significantly differ from subjects who had been diag-
nosed earlier and undergone levothyroxine therapy for
more than 5 years.
Patients were divided into three groups based on their
current TSH levels while taking Levothyroxine for treat-
ment. Patients with serum TSH levels of below 1.88,
1.88 to 3.40, and 3.41 to 5 showed no significant differ-
ence in terms of insulin resistance and hyperglycemia.
Also no meaningful difference in terms of the presence
of metabolic syndrome was detected among the groups
(P = 0.39).
Discussion
The results of current study revealed a high prevalence
of insulin resistance in hypothyroid patients whereas
they were in euthyroid state for more than one year with
Levothyroxine therapy (44.8%). Moreover, the prevalence
of elevated fasting insulin level was more significant in
those with highly positive Anti TPO antibodies (94.1%).
Table 2 Difference between the two groups of patients for frequency of obesity, central obesity, hyperchlosterolemia,
hypertriglyceridemia, low-HDL cholesterol and hyperglycemia
Parameters Post ablative hypothyroid (n:49) Hashimoto’s thyroiditis (n:46) Hashimoto’s thyroiditis with
highly positive TPO abs (n:17)
P value
Obesity 20(40.8%) 14(30.4%) 5(31.3%) 0.539
Central obesity 37(75.5%) 28(60.9%) 11(64.7%) 0.301
Hypertension 6(12.2%) 6(13%) 3(17.6%) 0.851
Hypercholesterolemia 6(12.2%) 5(10.9%) 1(5.9%) 0.767
Hypertriglyceridemia 17(34.7%) 19(41.3%) 4(28.6%) 0.639
Low-HDL cholesterol 15(30.6%) 14(30.4 %) 8(47.1%) 0.414
Hyperglycemia 13(26.5%) 13(28.3%) 4(23.5%) 0.931
Elevated fasting insulin level 36(71.4%) 27(62.8%) 16(94.1%) 0.05
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plasma Insulin, glucose and lipid concentration between
patients with and without Hashimoto’s thyroiditis diag-
nosed as the cause of their hypothyroidism.
In recent years, tremendous interest has been raised
in the effect of thyroid function on insulin levels. It is
established that clinical hypothyroidism is considered
as an insulin-resistant state [5,6]. Following their studies
on patients with hypothyroidism, Handisurya [14] and
Stanicka [15] have concluded that hypothyroidism makes
glucose inaccessible to insulin [16]. However; an exact
pathogenetic mechanism involved in insulin resistance in
hypothyroidism is still unknown. In current study with
enrolling different groups of hypothyroid patients, we
tried to detect any association of autoimmunity against
thyroid and insulin resistance. Adjusting for age and
sex, hypothyroid patients had more frequency of central
obesity than general population of Zanjan, the city that
this study was conducted (67% vs. 40%) [17]. Having
high prevalence of insulin resistance (44%) in our patients,
who all were euthyroid for a long time before the study,
reveals another mechanism other than the role of lowTable 3 Comparison of the biochemical and anthropometric p
serum levels of Anti-TPO Abs
Paremeters Negative Anti-TPO Abs N: 49 Positive Anti-TP
Age (year) 43.9 ± 1.8 40.9 ± 1.7
W.C (cm) 89.5 ± 3.2 91.6 ± 0.7
BMI (kg/m2) 28.5 ± 0.6 27.7 ± 0.7
SBP 113.2 ± 3.1 113.9 ± 2.6
DBP 72.1 ± 2 74.5 ± 2.2
TC (mmol/L) 189.2 ± 6 179.9 ± 6.5
TG (mmol/L) 134.4 ± 7.4 148.8 ± 13.6
HDL (mmol/L) 47.4 ± 1.4 47.2 ± 1.7
FPG (mmol/L) 93 ± 1.6 90.8 ± 2.1
OGTT 112.9 ± 3.7 113.3 ± 5.4
Insulin (uIU/mL) 8.9 ± 0.6 10.54 ± 1.5
HOMA-IR 2.1 ± 0.2 2.4 ± 0.4thyroid hormones for the insulin resistance in hypo-
thyroidism. Higher central fat in the subjects may explain
the higher prevalence of insulin resistance among partici-
pants, however; a significantly more prevalence of elevated
fasting insulin level was detected in a subgroup of patients
with Hashimoto’s thyroiditis and highly elevated levels
of Anti TPO antibodies more than 1000 IU/ml which
might support the concept of autoimmunity role in insulin
resistance. Regarding the metabolic indexes and insulin
resistance, no differences were found between hypothyroid
patients with and without autoimmunity against thyroid.
Positive effect of Levothyroxine on insulin resistance is
still under investigation. Robert Krysiak et al. [18] have
illustrated that a six-month treatment with levothyroxine
does not have a significant effect on HOMA-IR in
patients with hypothyroidism. Our results could support
this finding as although we have not considered the level
of glucose, lipid and insulin levels of our hypothyroid
patients before the initiation of treatment, they had yet
much more frequency of insulin resistance after a long
time of treatment as compared to the general population
[19]. Thus, a significant effect of replacement therapyarameters in three groups of patients based on their
O Abs N: 46 Highly positive Anti-TPO Abs N: 17 P value
37.2 ± 3.2 0.13
96.2 ± 3.1 0.58
30 ± 1.2 0.41
117.1 ± 5.8 0.91
78 ± 2.6 0.33
176.9 ± 11.7 0.46
145.2 ± 24.4 0.94
40.6 ± 1.2 0.04
89.6 ± 2.9 0.66
92.9 ± 6.4 0.09
11.07 ± 1 0.20
2.5 ± 0.3 0.29
Table 4 Relationship between the serum Anti TPO
antibody concentration and other variables
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patients seems to be unlikely.
Whether the treatment with Levothyroxine can affect
autoimmune background against thyroid or not is not
clear. Based on some studies [18,20] treatment with
Levothyroxine may attenuate the level of Anti TPO anti-
body in hypothyroid patients and patients whose hypo-
thyroidism is due to Hashimoto’s disease may benefit
more from Levothyroxine therapy [18]. On the other
hand, some other studies indicate that treatments with
Levothyroxine have not always successfully restored the
immunoglobulin to its normal levels [9].
Hypothyroidism could be considered as T helper1 disease
[21] in which pro-inflammatory cytokines such as TNF- α
and IL-6 play a crucial role [22,23]. There is a connection
between the level of TPO Abs and pro-inflammatory cyto-
kines like TNF-α and IL-6 [24]. The antibodies produced
against the antigens specific to the thyroid like TPO, result
in an immunity complex, which activates the complement
pathway and ultimately the T cells, thus leading to an
increase in the production of pro-inflammatory cytokines
[24]. Therefore, Anti-TPO Abs, which play a predictive role
in the progress of hypothyroidism can have either direct
cytotoxic effect for thyroid cells through the IgG1 class
[24,25], or indirect destructive effect on thyrocytes through
activating TH1 cells and increasing inflammatory responses
via release of inflammatory cytokines [26]. In addition,
the secretory function of monocytes and lymphocytes is
associated with the TPO Abs titer which can be accounted
for the fact that the interaction between the monocytes
and T cells activates B lymphocytes and produces TPO
Abs [18]. Monocytes, lymphocytes and cytokines pro-
duced by these cells play an essential role in triggering
autoimmunity disorders [27,28]. The monocytes, macro-
phages, lymphocytes coupled with the cytokines secreted
by these cells – in particular, TNF-α and IL-6 – contribute
to insulin resistance and atherosclerotic plaques [16,29].Studies have shown, Levothyroxine treatment increases
the number of CD8+ cells and may impedes the progress
of the disease [30,31]. As a result, the anti-inflammatory
effects of Levothyroxine could be accompanied by a
decrease in the TPO Abs titer. This implies that the
reduction in the TPO Abs titer stems from a drop in
the secretion of the cytokines involved in the under-
lying mechanism of the disease [18]. The findings of the
present study show that with the exception of patients
with high TPO Abs serum levels of above 1000 IU/ml,
insulin resistance is uninfluenced by existence of Anti
TPO antibody in hypothyroid patients being treated
with Levothyroxine, a fact which might be due to the
anti-inflammatory and curative effects of Levothyroxine.
Moreover, the present study shows that euthyroid
subjects in the highly positive Anti TPO Abs group
have lower serum HDL level than the rest of the sub-
jects (P = 0.04). Except to the subgroup of Hashimoto’s
thyroiditis with highly positive antibody levels, overall we
could not find any difference between patients with and
without autoimmunity regarding their lipid profile. There-
fore, if we consider any association between anti thyroid
antibodies and HDL-c or insulin resistance it might be
true just for much higher levels of autoantibodies. There
is a raft of research available concerning the effect of
Levothyroxine on lipid profile which illustrates that
levothyroxine can indeed help reduce total cholesterol
and LDL to a limited extent [31,32]. Yet, the effect of
Levothyroxine on the serum level of HDL remains unveri-
fied. Some studies maintain that levothyroxine exerts no
discernible effect on HDL serum levels [18,33]) whereas
others contend that it escalates HDL serum levels [32,34].
Our results were partially in line with Tamer et al. [35]
who have concluded that the thyroid autoimmunity dis-
order can be proved to be correlated with hyperlipidemia
and atherosclerosis, independent of the thyroid function.
According to the study, the serum level of TPO Abs bears
a negative relationship with HDL; which is confirmed in
another study where a positive correlation between Anti-
TPO Abs and cholesterol and LDL is also reported [36].
In conducting this research, few restrictions were en-
countered. The first one was the relatively limited size of
the samples. Obviously, a larger number of samples are
required to be able to extrapolate the results especially
in a subgroup with highly positive Anti TPO Abs. Secondly,
female subjects greatly outnumbered the males, thus
making it impossible to generalize the results for male
patients with hypothyroidism. Thirdly, all the participants
had been receiving levothyroxine and were euthyroid at
the start of this research. The strategy was selected in
the design of this study to eliminate the effect of hypothyr-
oxinemia itself, as a confounding factor, on the results.
However, as long as it is believed that Levothyroxine treat-
ment may cause some attenuation in the immune system’s
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would be more beneficial to include subjects who have
been recently diagnosed with hypothyroidism and have
not received any treatment yet in a separate study.
Conclusions
The present study demonstrated that there is no obvious
association between thyroid autoimmunity and meta-
bolic indexes of hypothyroid patients. Only patients with
Anti TPO antibody levels more than 1000 IU/ml may
experience higher insulin level and less HDL-c with the
same BMI. More studies with higher sample size of
patients with highly positive antibodies would be more
informative.
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